Loading
Every dated change on the records linked to Hairy cell leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Relapsed/refractory hairy cell leukaemia after ≥2 systemic therapies including a purine analogue
First CD22 immunotoxin; withdrawn from the US market in 2023 for commercial reasons.